Biohit Oyj

Biohit Oyj is a Finnish biotechnology company that operates on a global scale, focusing on the development of diagnostic products and health-promoting supplements. Established in 1988, the company is headquartered in Helsinki, Finland, with subsidiaries in Italy and the United Kingdom. Biohit's mission, 'Innovating for Health,' drives its commitment to addressing global health challenges through innovative solutions. The company's shares are listed on the NASDAQ OMX Helsinki in the Small Cap Healthcare group.

46

2.56

2.34

— Biohit Oyj
%
Diagnostic Tests40% Includes tests for various health conditions, particularly gastrointestinal issues.
Acetaldehyde-binding Products25% Products designed to bind acetaldehyde, a harmful compound.
Monoclonal Antibodies15% Used in various diagnostic and therapeutic applications.
Licensing20% Licensing of Biohit's intellectual property to other manufacturers.

Biohit's customer base includes healthcare providers, diagnostic laboratories, and pharmaceutical companies...

  • Healthcare Providersprimary

    Purchase diagnostic tests for patient care.

  • Diagnostic Laboratoriesprimary

    Use Biohit's tests for accurate diagnostics.

  • Pharmaceutical Companiessecondary

    Acquire monoclonal antibodies for research and development.

  • Manufacturerssecondary

    License Biohit's IP to produce and sell products.

Biohit operates globally with a significant presence in Europe, Asia, and South America...

  • Headquartered in Helsinki, Finland
  • Subsidiaries in Italy and the UK
  • Key markets include Europe and Asia
  • 98.5% of revenue comes from exports
  • Active participation in international health technology exhibitions

Biohit's strategic priorities focus on addressing global health challenges through innovation and collaboration...

01
Innovation in Gastrointestinal Healthmedium-term

To address the increasing prevalence of digestive disorders.

02
Regulatory Adaptationshort-term

To comply with new EU IVDR regulations.

03
Market Expansionlong-term

To increase global reach and sales.

Biohit faces several risks, including regulatory compliance challenges and the need for successful product...

critical

Geopolitical Exposure

Significant sales in China.

Materiality
high
high

Regulatory Compliance

Varied registration processes across markets.

Materiality
high
medium

Market Volatility

Investment portfolio exposed to market changes.

Materiality
medium
Revenue Recognition
high
Licensing Agreements
medium
Lease Accounting
medium

: 11/08/2026